These results suggest that IgE may be produced in the airways of infants in response to RSV infection. The relationships between IgE production, RSV infection, and symptoms of acute bronchiolitis remain obscure. (Arch Dis Child 1995; 72: 64-69) 
Abstract
It has been proposed that a specific IgE response contributes to the immunopathology of acute respiratory syncytial virus (RSV) bronchiolitis but previous work has been difficult to replicate. Indirect evidence that might support this contention was sought by measuring total IgE concentrations in bronchoalveolar lavage (BAL) samples obtained from intubated infants and by attempting to detect mRNA for IgE in cells obtained from both the upper and lower respiratory tract. Evidence of significant mast cell activation was sought by measuring tryptase concentrations in BAL fluid and serum.
Detectable concentrations of IgE were found in two of seven BAL samples obtained more than five days after intubation and mRNA for IgE was demonstrated in three of six BAL samples and three of six samples obtained from the upper respiratory tract. Tryptase was detectable in 11 of 12 BAL samples with the two highest values detected on day 1. These values were raised compared with control samples but were not such to suggest that mast cell degranulation is the major contributor to the inflammatory process.
These results suggest that IgE may be produced in the airways of infants in response to RSV infection. The relationships between IgE production, RSV infection, and symptoms of acute bronchiolitis remain obscure. Respiratory syncytial virus (RSV) is responsible for yearly epidemics of acute bronchiolitis and remains a major cause of morbidity in infancy.' 2 For more than 20 years workers have been pursuing a variety of possible immunopathological mechanisms that might explain why some infants should develop such a distinctive disease while most who become infected simply develop upper respiratory tract symptoms.3 One of the earliest theories proposed that acute bronchiolitis may result from a type I hypersensitivity reaction involving IgE,4 and that the infants had previously encountered the virus earlier in the winter epidemic and developed acute bronchiolitis when subsequently re-exposed to the virus. Subsequent epidemiological studies argued convincingly that prior exposure was most unlikely in that the age distribution of the illness did not change as the epidemic progressed, and the curves representing the incidence of upper respiratory tract illness and that of bronchiolitis are essentially parallel. 5 Further it was well recognised that these infants do not demonstrate an accelerated secondary antibody response to the virus during the acute illness and indeed those affected usually have delayed or absent response.
The possibility that IgE might be involved in the genesis of the disease was again raised more than a decade ago by a group who produced results suggesting that some infants infected by the virus produce a RSV specific antibody response detectable in nasal secretions. [6] [7] [8] [9] [10] Their studies have shown that this response appears to be detected more commonly in those with lower respiratory tract disease while peak concentrations tend to correlate with both severity of the acute illness, as determined by the degree of hypoxia,7 and the prevalence of subsequent symptoms.9 The magnitude of this response does not appear to be age related.
Unfortunately these results have proved very difficult to reproduce,1' although one study has produced similar results correlating serum RSV IgE and IgG4 concentrations with the likelihood of wheeze.12
There have been several studies showing that atopy is not an important predisposing factor for developing acute bronchiolitis, '3-15 and that serum IgE is not increased in an epidemic of bronchiolitis. 16 Therefore it would appear that these infants are not genetically predisposed to producing increased IgE concentrations. Hence, if a mucosal IgE response is induced by the virus, this must be due to the virus's ability to modulate the host immune response in some way.
It is important to determine whether a predominant IgE response does occur in these infants for a number of reasons. Previous attempts to produce a vaccine have been either unsuccessful,17 or have resulted in abnormally severe disease in infants after natural infection by the virus.18 Hence clarification of the immunological mechanisms involved in the host-virus interaction in infants with RSV bronchiolitis may be essential if a safe and effective vaccine is to be produced. Furthermore, any antibody response will be a primary response as these infants have not previously encountered the virus. It is therefore possible that if an RSV specific IgE response is occurring in these infants then this might be the one situation in which this response can be studied in humans.
In this study we sought to obtain indirect evidence for an IgE response by measuring total IgE concentrations in bronchial lavage samples and using a polymerase chain reaction (PCR) method to identify mRNA for IgE in cells obtained from the upper and lower respiratory tract. Tryptase, a mast cell specific mediator, was also measured in bronchial lavage fluid and serum.
Patients and methods

PATENTS
All patients enrolled in the study were previously healthy infants who were admitted with a diagnosis of RSV bronchiolitis confirmed by indirect immunofluorescence on nasopharyngeal aspirates. All were under 6 months of age at the time of admission. Bronchoalveolar lavage (BAL) samples were obtained from a total of 12 patients intubated for RSV bronchiolitis. Total IgE or tryptase concentrations were measured in the resulting supernatant, while cells obtained from the upper and lower respiratory tract were processed in order that mRNA could be identified. Because of the small volume of fluid recovered after BAL, the resulting supernatant from each sample was used only in one aspect of the study. Twenty one nasopharyngeal samples were used from these patients for mRNA analysis and serum samples were obtained from intubated and non-intubated patients for measurement of tryptase. Ethics committee approval was obtained for this study and informed consent obtained from parents.
Total 12 randomly selected samples from a total of 21 BAL and 21 nasopharyngeal samples obtained at varying time intervals after intubation. Six of these samples were obtained from BAL and six from nasopharyngeal aspirates. In four samples in which mRNA for T cell receptor was detected, evidence of mRNA for interleukin-4 and interferon gamma synthesis was also sought.
Tryptase values were assayed in 12 BAL samples obtained from four patients. Samples were obtained within 24 hours of admission and at least one repeat sample was obtained from each patient during the next four days. A further 11 bronchial lavage samples were obtained from 10 patients intubated for non-respiratory conditions and these were used as controls. These patients had had cardiac surgery (eight), abdominal surgery (one), and surgery for burns (one). These were obtained as soon after intubation as possible with one repeat sample being obtained four days after intubation.
For analysis of serum tryptase, 11 samples from 11 non-ventilated patients and 20 samples from 14 ventilated patients were obtained as soon after admission or intubation as possible and repeat samples were obtained between one and three days later in four ventilated subjects. Control samples were collected from 15 healthy infants (aged from 1-5 months), blood being obtained from a cannula inserted preoperatively in healthy infants undergoing routine repair of inguinal hernia. The children were anaesthetised with gaseous agents at the time the cannulas were inserted.
COLLECTION OF SAMPLES
Nasopharyngeal aspirates were obtained using a standard technique with a catheter being introduced into the nasopharynx through the nose and 8 kPa of suction being applied as the catheter was withdrawn.
Bronchial lavage was performed at the time of routine endotracheal suction using a technique based on one previously described for obtaining lavage samples from preterm infants with chronic lung disease.19 Infants were oxygenated for two minutes before the procedure. A suction catheter was passed through the endotracheal tube with the infants head turned to the left. This was designed to introduce the suction catheter into the right main bronchus. Normal saline at 1 ml/kg was warmed to 37°C and introduced through the catheter in to the right main bronchus and after a five second delay aspirated using 8 kPa of suction. The aspirate was collected into a trap that was placed on ice until processed.
PROCESSING OF SAMPLES
The tracheal aspirates and nasopharyngeal aspirates were placed in a centrifuge tube and agitated with a pipette to break up mucus in the sample. Larger aggregates of mucus were removed with a pipette and the lavage fluid was allowed to stand. Fine debris was removed from the surface with a pipette and the remaining fluid removed leaving heavy debris at the base of the tube. The samples were placed in a second tube and centrifuged at 300 g for five minutes, the supernatant then being removed and frozen at -70°C to be analysed subsequently. The pellet of cells was then resuspended in normal saline.
TOTAL IgE AND ALBUMIN ASSAY
Total IgE concentrations in bronchial lavage were assayed using the Pharmacia CAP system that utilises a double antibody sandwich technique. Standards used in this assay were calibrated against the first IRP 75/502. Albumin was assayed using a rate nephelometry technique using a Beckman Array immunochemistry analyser. Standards used in this assay are calibrated against IFCC 74/1.
ISOLATION AND ANALYSIS RNA
A technique based on that described by Gough20 was used where cells were placed in a 1-5 ml Eppendorf tube to which 2 RI of RNA guard (Pharmacia) were added and the cells were resuspended in 200 RI of ice cold solution 1 (10 mM Tris-hydrochloric acid, pH 7-5, 0 1 M sodium chloride, 1X5 mM magnesium chloride, and 0*65% NP-40). The cells were then vortexed and centrifuged at 6500 rpm for five minutes to pellet the nuclei. Supernatant was transferred to a fresh tube containing 200 ,u of solution 2 ( 7 M urea, 1% SDS, 0.35 M sodium chloride, 10 mM EDTA, 10 mM Tris-hydrochloride acid, pH 7.5) and 400 pt of a phenol/chloroform mixture (phenol/chloroform/isoamyl alcohol (50:50:1) saturated with TE buffer (100 mM Tris, 50 mM EDTA, pH 7 5)) and vortexed vigorously. This was centrifuged at 13 000 rpm for three minutes and the supernatant removed to a fresh tube. Two volumes of 100% ethanol and 0 1 volume of three molar sodium acetate were added and the cells left to precipitate at -200C overnight. These were spun in the microcentrifuge at 13 000 rpm for 15 We chose to study samples from the respiratory tract in an attempt to determine whether an IgE response does occur as there is good evidence that significant local production of IgE occurs within the respiratory tract,23 24 and it is probable that circulating concentrations of IgE do not reflect events at the epithelial surface. One study from Welliver et al has suggested that this is the case for the RSV specific IgE response.8 Samples from both the upper and lower respiratory tract were studied as it is unclear from previous studies whether results obtained from using nasal samples are representative of events in the lung.
In this study we did find detectable concentrations of total IgE in two samples obtained six and eight days after intubation, whereas no IgE had been detected in earlier samples from these patients. We did not measure serum IgE concentrations in these two patients but neither of them came from atopic families. If we assume that their serum albumin concentration was 30 g/l, serum IgE concentrations of 411 IU/l and 2272 IU/l would be required to produce similar IgE/albumin concentrations. This is highly improbable and suggests that the IgE detectable in the BAL samples is not derived from serum. As the concentrations of IgE detected in two samples from the first winter were very close to the lower limit of this method's sensitivity, samples obtained during the second winter were concentrated in an attempt to increase the likelihood of detecting IgE. This has been done in previous studies attempting to identify IgE in BAL samples from adult subjects.23 25 Despite concentrating samples between five and 10-fold, no IgE was detected in BAL samples. If IgE is being produced during a primary RSV infection, our failure to detect it in all but two subjects may have a number of explanations. It is possible that even after concentrating samples, concentrations will remain below the limit of detection in most subjects during the first week after developing acute bronchiolitis. Alternatively, it is possible that locally produced IgE is destroyed before being assayed as we did not add a protease inhibitor to these samples. Previous studies assaying total23-25 and RSV specific IgE7-10 have not used protease inhibitors and have been able to detect this immunoglobulin, but concentrations measured in this study were close to the limit of detection and any reduction due to the action of proteases may have reduced concentrations below that detectable by this method. The albumin concentrations in BAL samples were significantly higher than noted in previous studies in which BAL fluid was obtained from adult subjects,23 25 and this is likely to reflect the intensity of the inflammatory process in these infants.
Messenger RNA for IgE was detected in 50% of samples obtained from both the upper and lower respiratory tract. The significance of these results is again difficult to interpret. We do not have control samples and as this technique is not quantitative, it is difficult to determine how significant such a result might be. Furthermore, simply detecting the presence of mRNA does not necessarily imply that IgE is being produced as post-transcriptional modification may result in failure to release a product coded for by such a message. However, in the context of previous studies this finding is of interest and needs pursuing.
No mRNA for either interleukin-4 or interferon gamma was detected in four samples in which a positive signal for T cell receptor was obtained. Both play an important part in antibody isotype switching26 with interleukin-4 having a central role in directing the antibody response towards a predominantly IgE response and interferon gamma having the opposite effect. It is possible that interleukin-4 is involved in the immune response but Went undetected, either because this cytokine's production is maximal before clinical symptoms have occurred or, alternatively, the mRNA for interleukin-4 is degraded by proteases within the bronchial secretions despite the use of 'RNA guard'. It does appear that the influence of this cytokine occurs very early during the activation of B cells and hence its influence may be established well before samples were obtained. Despite the intense inflammation within the airways, mRNA for IgE and T cell receptor could be detected in some samples and hence it would appear unlikely that selective destruction would account for failure to detect mRNA for this cytokine. The failure to detect mRNA for interferon gamma in clinical samples using this method is extremely unusual but is consistent with the results of previous studies that have failed to detect interferon gamma in either the upper27 28 
